

Johannes Wiegand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028047/publications.pdf>

Version: 2024-02-01

78
papers

3,879
citations

186265

28
h-index

123424

61
g-index

81
all docs

81
docs citations

81
times ranked

4858
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
2	M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. <i>Digestive and Liver Disease</i> , 2022, 54, 358-364.	0.9	5
3	Age Dependence of Liver Enzymes: An Analysis of Over 1,300,000 Consecutive Blood Samples. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 641-650.	4.4	14
4	Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 76-83.	1.6	6
5	Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 686-692.	1.6	3
6	Comparison of the certified Copan eSwab™ system with commercially available cotton swabs for the detection of multidrug-resistant bacteria in rectal swabs. <i>American Journal of Infection Control</i> , 2022, , .	2.3	0
7	Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 451.	3.2	4
8	Response to “Age dependence of liver enzymes: celiac disease should also be considered” (CGH-D-22-00387). <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
9	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. <i>Pathogens</i> , 2022, 11, 517.	2.8	20
10	Endoscopic Bariatric Treatment with Duodenal-jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2022, 32, 2495-2503.	2.1	6
11	Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. <i>Gut</i> , 2021, 70, 219-221.	12.1	8
12	Hepatitis C “committing the world to an eradication of the infection. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 96-99.	1.5	0
13	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	8.1	130
14	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
15	The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings. <i>Viruses</i> , 2021, 13, 2327.	3.3	6
16	From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. <i>Pathogens</i> , 2021, 10, 1570.	2.8	3
17	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , 2020, 2, 100168.	4.9	18
18	Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. <i>Scientific Reports</i> , 2020, 10, 18345.	3.3	19

#	ARTICLE	IF	CITATIONS
19	Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 706-711.	1.5	7
20	Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1493-1495.	2.0	5
21	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	8.1	58
22	SAT-277-Screening diabetic patients at risk for complications of nonalcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations. <i>Journal of Hepatology</i> , 2019, 70, e757-e758.	3.7	1
23	Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. <i>Bone Marrow Transplantation</i> , 2019, 54, 1738-1746.	2.4	13
24	Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1424-1431.	1.6	5
25	Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation – A Simple Intervention Ensures High Adherence. <i>Annals of Transplantation</i> , 2019, 24, 527-531.	0.9	10
26	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 989-1000.	3.7	47
27	Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 280-283.	1.6	7
28	Editorial: the impact of steatosis on liver stiffness quantification is minimal – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1417-1418.	3.7	0
29	Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 76-82.	1.5	1
30	Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society. <i>Digestive and Liver Disease</i> , 2018, 50, 731-733.	0.9	3
31	Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?. <i>Hepatology</i> , 2017, 65, 2126-2128.	7.3	3
32	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
33	Collaboration, Not Competition: The Role of Magnetic Resonance, Transient Elastography, and Liver Biopsy in the Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 479-481.	1.3	14
34	Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 58, 246-252.	2.3	14
35	Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. <i>Journal of Translational Medicine</i> , 2017, 15, 106.	4.4	30
36	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , 2017, 17, 215-222.	9.1	109

#	ARTICLE	IF	CITATIONS
37	Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. <i>Hamostaseologie</i> , 2017, 37, 127-130.	1.9	9
38	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 187-192.	1.6	7
39	HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre. <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 231-237.	0.5	8
40	Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 543-544.	3.7	9
41	Clinical Trial Watch: Reports from the Liver Meeting® [®] , AASLD, San Francisco, November 2015. <i>Journal of Hepatology</i> , 2016, 64, 1428-1445.	3.7	3
42	Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. <i>Annals of Transplantation</i> , 2016, 21, 368-372.	0.9	1
43	Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques. <i>World Journal of Gastroenterology</i> , 2015, 21, 4894.	3.3	37
44	Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. <i>PLoS ONE</i> , 2015, 10, e0141649.	2.5	47
45	Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. <i>Journal of Hepatology</i> , 2015, 62, 1256-1264.	3.7	75
46	Noninvasive characterization of graft steatosis after liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 224-232.	1.5	28
47	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. <i>PLoS ONE</i> , 2014, 9, e91987.	2.5	130
48	Therapy of Liver Abscesses. <i>Viszeralmedizin</i> , 2014, 30, 334-341.	0.0	63
49	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	2.0	161
50	Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1342-1344.	3.7	16
51	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	2.0	372
52	Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 195-208.	4.7	61
53	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 497-506.	9.1	84
54	The Etiology, Diagnosis and Prevention of Liver Cirrhosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 85-91.	0.9	119

#	ARTICLE	IF	CITATIONS
55	Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS ONE, 2013, 8, e67481.	2.5	11
56	Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scandinavian Journal of Gastroenterology, 2012, 47, 1353-1361.	1.5	35
57	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. Journal of Hepatology, 2012, 57, 260-266.	3.7	22
58	A Common Variant of PNPLA3 (p.I148M) Is Not Associated with Alcoholic Chronic Pancreatitis. PLoS ONE, 2012, 7, e29433.	2.5	15
59	Non-Invasive Evaluation of Cystic Fibrosis Related Liver Disease in Adults with ARFI, Transient Elastography and Different Fibrosis Scores. PLoS ONE, 2012, 7, e42139.	2.5	49
60	Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scandinavian Journal of Gastroenterology, 2011, 46, 1458-1467.	1.5	102
61	Quantification of HBsAg and HBV-DNA during Therapy with Peginterferon alpha-2b plus Lamivudine and Peginterferon alpha-2b Alone in a German Chronic Hepatitis B Cohort. Zeitschrift Fur Gastroenterologie, 2011, 49, 1463-1469.	0.5	3
62	Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. Clinical Infectious Diseases, 2011, 53, 1111-1114.	5.8	3
63	Interferon-Î±-Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 1885-1897.e10.	1.3	177
64	Resistance management in chronic hepatitis B complicated by renal failure. Clinical Nephrology, 2010, 74, 53-58.	0.7	6
65	HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. Journal of Viral Hepatitis, 2009, 17, 631-9.	2.0	9
66	Newly acquired hepatitis Câ€™ many hurdles from diagnosis until treatment initiation. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1782-1784.	2.8	4
67	Medical procedures as a risk factor for HCV infection in developed countries: Do we neglect a significant problem in medical care?. Journal of Hepatology, 2008, 48, 1019-1020.	3.7	25
68	Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon Î±. Journal of Antimicrobial Chemotherapy, 2008, 62, 860-865.	3.0	40
69	Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antiviral Therapy, 2008, 13, 211-20.	1.0	39
70	Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence. Antiviral Therapy, 2008, 13, 211-220.	1.0	115
71	Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antiviral Therapy, 2007, 12, 303-16.	1.0	6
72	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-Î±2b therapy for Acute Hepatitis C. Antiviral Therapy, 2007, 12, 303-316.	1.0	22

#	ARTICLE	IF	CITATIONS
73	Treatment of Acute Hepatitis C—How to Explain the Differences?. <i>Gastroenterology</i> , 2006, 131, 682-683.	1.3	5
74	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006, 43, 250-256.	7.3	229
75	Reply:. <i>Hepatology</i> , 2006, 44, 511-512.	7.3	2
76	Budesonide in previously untreated autoimmune hepatitis. <i>Liver International</i> , 2005, 25, 927-934.	3.9	86
77	Severe Exacerbation of Chronic Hepatitis B after Emergence of Lamivudine Resistance in a Cirrhotic Patient: Immediate Switch to Adefovir Dipivoxil Appears to be Indicated. <i>Zeitschrift Fur Gastroenterologie</i> , 2004, 42, 15-18.	0.5	17
78	Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , 2004, 40, 98-107.	7.3	80